Life Sciences Tools and Services
Company Overview of Accelovance, Inc.
Accelovance, Inc., a contract research organization (CRO), provides site management organization, patient recruitment, and clinical call center services. The company focuses on oncology, vaccines, and general medicine to pharmaceutical and biotech industries. Its CRO services include protocol development, project management, clinical trial monitoring, data management, biostatistics, pharmacovigilance, regulatory affairs, and medical writing services. The company also provides clinical call center services, such as recruitment/retention/compliance, post approval safety studies, phase IV studies, surveillance programs, patient-reported outcomes, observational studies, registries, site support ...
2275 Research Boulevard
Rockville, MD 20850
Founded in 2004
Key Executives for Accelovance, Inc.
Founder, Chief Executive Officer and President
Senior Vice President of Clinical Development
Managing Director of Accelovance Europe
Compensation as of Fiscal Year 2015.
Accelovance, Inc. Key Developments
Panacea Pharmaceuticals, Inc. Engages Accelovance, Inc. for Clinical Development of its Novel Nanoparticle-Based Therapeutic Cancer Vaccine
Feb 10 15
Panacea Pharmaceuticals, Inc. and Accelovance Inc. announced the establishment of a clinical development services agreement to develop and advance Panacea's oncology immunotherapy pipeline. Through this agreement, Accelovance will support Panacea's clinical development strategies by offering scientific/medical and regulatory expertise, in addition to providing Contract Research Organization (CRO) support through Project Management, Clinical Monitoring, Data Management, Biostatistics, and Safety services for Panacea's clinical trials. The Panacea and Accelovance partnership will bring together highly complementary capabilities to advance and expedite Panacea's drug development and clinical advancement. Under the agreement, Panacea will maintain stringent oversight and quality standards relating to patient safety and regulatory compliance, with Accelovance assisting with the development and implementation of clinical strategies. Panacea will rely on Accelovance's knowledge in the areas of vaccines, oncology, and clinical management. Providing advanced insight into Panacea's development pipeline will enable both organizations to enhance operational planning, consistency, and execution.
Accelovance, Inc. Appoints Joseph D. Purvis as Vice President of Medical Affairs, Oncology
Sep 30 14
Accelovance, Inc. announced that Dr. Joseph D. Purvis has joined the company as Vice President Medical Affairs, Oncology. Dr. Purvis brings more than 25 years of oncology drug development experience to Accelovance, having provided significant contribution in the development, approval, and postmarketing development of multiple cytotoxic, biological, targeted, and hormonal products; including: IV Alkeran, IV Zyloprim, Navelbine, Eloxatin, Nolvadex, Faslodex, Arimidex, Casodex, Iressa, and Torisel. He has extensive regulatory experience, especially with the FDA and EMA, and has worked with community and academic oncologists and oncology cooperative groups. Dr. Purvis is an alumnus of Haverford College and of Jefferson Medical College. Dr. Purvis will be based in Accelovance's Raleigh Durham, NC office.
Accelovance Announces Opening of Research Triangle Park, North Carolina Office
Feb 19 14
Accelovance announced the opening of a new office in Research Triangle Park (RTP), North Carolina. This office opening supports continued corporate expansion and provides Accelovance's clients and employees with a presence in the research-active landscape of the RTP area of North Carolina. The new offices are close to many current and potential clients and offer a rich base of technical talent to support continued corporate growth. Accelovance plans to add up to 15 new clinical operations positions in the RTP area in 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions